DowDuPont completes FMC acquisition, bolsters excipient biz

By Dan Stanton contact

- Last updated on GMT


Related tags: Medicine, Fmc

The acquisition of FMC Corporation's health and nutrition business gives DowDuPont “one of the broadest pharma offerings to serve the growing excipients industry,” the firm says.

DowDupont has completed an asset swap, adding FMC’s health and nutrition business (except for the Omega-3 business) in exchange for a portion of DuPont's Crop Protection business and $1.6bn.

DuPont first announced the deal in March​, ahead of its planned $130bn megamerger with Dow Chemical which itself was completed on September 1​.

And speaking on the first financial conference call as a merged entity last week, DowDuPont CEO Edward Breen said the combination of FMC’s assets with Dow Pharma and Food put the firm in a strong position in the pharmaceutical excipient space.

“Our portfolio now has one of the broadest pharma offerings to serve the growing excipients industry. We can now provide customers with capabilities to blend and integrate requirements for controlled release, binding and solubility, and emerging needs,” ​he told investors.

“Our new pharma excipients business unit created from the integration of Dow and FMC also gives us a stronger position in the healthcare market when combined with our other initiatives in medical silicones, medical packaging and emerging bio-based products.”

He added further information on DowDuPont’s pharma strategy will be shared in the future “as we continue to advance and implement our plans.”

For the third quarter 2017, the firm’s Nutrition & Biosciences division (part of a rejig under the specialty products business, which now includes pharma​) remained relatively flat year-on-year at $1.47bn. The result only includes one month of DuPont earnings, and none of FMC's.

Related news

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us


View more